BLPH News and Press, Bellerophon Therapeutics Inc. From 11/13/23

Bellerophon Therapeutics Inc. (BLPH) is expected to report for Q3 2023

2023-07-25 09:52:47 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mobileye (NASDAQ: MBLY ) stock is on the move Tuesday after Morgan Stanley analyst Adam Jonas renewed coverage of the driver assistance systems company. With that comes the ...

2023-07-25 09:35:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ: BIIB ) layoffs are on the way as the company seeks further profits with its new Alzheimer’s disease drug launch. This has the pharmaceutical company p...

2023-07-25 08:46:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bellerophon Therapeutics (NASDAQ: BLPH ) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice . The Listing Qualifi...

2023-06-19 06:00:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One reason we invest in the stock market is that we’re all looking to secure our financial futures. We want to be comfortable in our retirements and provide for our families and even fut...

2023-06-05 13:06:50 ET Gainers: Forza X1 ( FRZA ) +164% . Sono Group ( SEV ) +123% . Chijet Motor Company ( CJET ) +62% . CIRCOR International ( CIR ) +51% . Timber Pharmaceuticals ( TMBR ) +44% . TOP Financial Group ( TOP ...

2023-06-05 10:06:47 ET Gainers: Timber Pharmaceuticals ( TMBR ) +36% . Amedisys ( AMED ) +15% . Rockwell Medical ( RMTI ) +15% . Coeptis Therapeutics ( COEP ) +14% . BiondVax Pharmaceuticals ( BVXV ) +12% . Losers: Bellerophon ...

2023-06-05 08:14:50 ET Bellerophon Therapeutic ( BLPH ) -71% announces top-line data from phase 3 REBUILD clinical trial of INOpulse® for treatment of fibrotic interstitial lung disease. Mallinckrodt MNK -18% to consider filing for bankruptcy again - WSJ. ...

Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-Sarcoidosis Co...

2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...